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ABSTRACT
Background The combination of developmental delay,
facial characteristics, hearing loss and abnormal fat
distribution in the distal limbs is known as Pierpont
syndrome. The aim of the present study was to detect
and study the cause of Pierpont syndrome.
Methods We used whole-exome sequencing to analyse
four unrelated individuals with Pierpont syndrome, and
Sanger sequencing in two other unrelated affected
individuals. Expression of mRNA of the wild-type
candidate gene was analysed in human postmortem
brain specimens, adipose tissue, muscle and liver.
Expression of RNA in lymphocytes in patients and
controls was additionally analysed. The variant protein
was expressed in, and puriﬁed from, HEK293 cells to
assess its effect on protein folding and function.
Results We identiﬁed a single heterozygous missense
variant, c.1337A>C (p.Tyr446Cys), in transducin β-like 1
X-linked receptor 1 (TBL1XR1) as disease-causing in all
patients. TBL1XR1 mRNA expression was demonstrated
in pituitary, hypothalamus, white and brown adipose
tissue, muscle and liver. mRNA expression is lower in
lymphocytes of two patients compared with the four
controls. The mutant TBL1XR1 protein assembled
correctly into the nuclear receptor corepressor (NCoR)/
silencing mediator for retinoid and thyroid receptors
(SMRT) complex, suggesting a dominant-negative
mechanism. This contrasts with loss-of-function germline
TBL1XR1 deletions and other TBL1XR1 mutations that
have been implicated in autism. However, autism is not
present in individuals with Pierpont syndrome.
Conclusions This study identiﬁes a speciﬁc TBL1XR1
mutation as the cause of Pierpont syndrome. Deletions
and other mutations in TBL1XR1 can cause autism. The
marked differences between Pierpont patients with the
p.Tyr446Cys mutation and individuals with other
mutations and whole gene deletions indicate a speciﬁc,
but as yet unknown, disease mechanism of the TBL1XR1
p.Tyr446Cys mutation.
INTRODUCTION
In 1998 Pierpont and coworkers described two
unrelated boys with remarkably similar faces (high
forehead, underdeveloped mid-face, narrow palpe-
bral ﬁssures and anteverted nares), short stature,
hearing loss, developmental delay and distinctive
palmar and plantar fat pads.1 Two similar patients
were subsequently reported, including one with a
choroid plexus papilloma, whereupon the condi-
tion was named Pierpont syndrome.2 3 While
several patients resembling Pierpont syndrome have
been reported,4 clinical re-evaluation and molecular
analyses have shown that they had either
Cofﬁn–Siris5 or Wiedemann–Steiner syndrome
(H. Brunner, personal communication 2013).
Initially this caused uncertainty about the pheno-
type deﬁning Pierpont syndrome, but the character-
istics of both Wiedemann–Steiner syndrome and
Cofﬁn–Siris syndrome are better known nowadays
and allow easy differentiation from the phenotype
in the reported patients with Pierpont syndrome.2 3
Until now, the cause of Pierpont syndrome has
remained unknown. However, de novo autosomal-
dominant mutations were suspected to be the most
likely cause.2
For the present study, we collected DNA from
two newly identiﬁed and four earlier-reported
patients with Pierpont syndrome. We performed
whole-exome sequencing in four patients and in
the parents of one of them, and identiﬁed identical
de novo missense mutations in the transducin β-like
1 X-linked receptor 1 (TBL1XR1) gene in all four
patients. Sanger sequencing of the two newly diag-
nosed patients revealed the same mutation.
TBL1XR1 is part of the nuclear receptor corepres-




The study cohort consisted of six unrelated patients
with Pierpont syndrome (table 1). The clinical diag-
nosis was based on the combination of the facial
characteristics, palmar and plantar fat pads, and
global developmental delay (ﬁgure 1). The descrip-
tion of patients 1–4 has been published.1–3
Blood samples were obtained from all patients
and their (unaffected) parents. Informed consent
for the study was obtained from the parents of all
patients. The Medical Ethics Committee of the
Academic Medical Centre in Amsterdam
(NL45117.018.13) approved the study.
Molecular analysis
Targeted enrichment and massive parallel sequen-
cing were performed on genomic DNA extracted
from circulating leucocytes of four patients and the
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parents of one of them. Enrichment of the whole exome was
performed using the Nimblegen SeqCap EZ Library V.3.0
(Roche). Each captured library was then loaded on a
SOLiD5500xl platform (Applied Biosystems) (patient 20120174
and unaffected parents 20112227 and 20112228, and patients
20112226, 20121069 and 20121072). Paired-end and single-
end sequence reads were aligned to hg19 using the Lifescope
aligner (V.2.5.1) (Applied Biosystems). Presumed PCR duplicates
were discarded using Picard Tools (http://picard.sourceforge.net)
in case of single-end reads or Lifescope when dealing with
paired-end reads. Local realignment and base-quality-score reca-
libration were performed with the Genome Analysis Toolkit
(GATK2 V.2.2-5-g3bf5e3f).6
For reads mapping to the human genome reference, mean
target region coverage for 20112226 and the trio was 94.5%,
with average sequencing depth on target of 92× and for
samples 20121069 and 20121072, respectively, 90.5% and
69×. Calls of SNPs and small insertions and deletions (INDELs)
were based on 18 unrelated exomes using the GATK Uniﬁed
Genotyper algorithm, and categorised based on their matching
quality, depth of coverage, base quality, the combination of base
quality and depth, the position of the alternate allele in the
read, and strand bias.7 8 Variants were functionally annotated
using KGGSeq v0.4 applying available public datasets from the
1000 Genomes Project, NHLBI GO Exome Sequencing Project
and dbSNP (V.137), and predictions were made regarding prob-
abilities of being disease causing. Only variants passing all
applied GATK ﬁlters, predicted to be a de novo mutation within
the trio and disease-causing by KGGSeq were retained.
Protein characterisation
The structure of the WD40 domain of TBL1XR1 was obtained
from the Protein Data Bank (PDB accession code 4LG9). For
expression in mammalian cells, constructs of TBL1XR1,
HDAC3 and GPS2-SMRT chimaera were cloned into the
pcDNA3 vector. Transient transfections and protein puriﬁca-
tions were performed as described elsewhere.9 For the
TBL1XR1/HDAC3/GPS2-SMRT chimaera complex, the
GPS2-SMRT chimaera contained an N-terminal 10×His-3×Flag
tag and a tobacco etch virus (TEV) protease cleavage site.
HEK293F cells (Invitrogen) were cotransfected with mixtures of
both tagged and untagged constructs using polyethylenimine
(PEI) (Sigma). To transfect 60 mL of cells, 60 mg DNA total was
diluted in 6 mL of phosphate-buffered saline (PBS) (Sigma) and
vortexed brieﬂy; 240 mL of 0.5 mg/mL PEI was added, then vor-
texed brieﬂy, and incubated for 20 min at room temperature,
then added to 60 mL cells (ﬁnal density 1×106 cells/mL). Cells
were harvested 48 h after transfection. For the interaction
studies the cells were lysed by sonication in 50 mM Tris/Cl pH
7.5, 100 mM potassium acetate, 5% v/v glycerol, 0.3% v/v
Table 1 Main clinical features of presently described individuals with Pierpont syndrome, including updates of the published patients 1 and 2,1
32 and 43
Patient 1 2 3 4 5 6 Total
Age (years) 28 20 12 5.7 10 19
Gender M M M M F F 4M/2F
Growth parameters at birth*
Length (cm) 45.7 (<P3) X 50.0 (P50) 48.5 (P10) 43.0 (<P3) 51 (P75)
Weight (kg) 3.0 (P25) 3.62 (P50) 2.64 (P10) 2.95 (P25) 2.43 (P3) 2.95 (P25)
OFC (cm) 35.5 (P75) X 33.8 (P25) 32.0 (P5) 28.0 (<P3) 33 (P25)
Growth parameters at age (years) 27 18 12 5.7 10 18
Height (cm) 147 (<P3) 147 (<P3) 128 (<P3) 100 (<P3) 109 (<P3) 144 (<P3)
Weight (kg) 36 (<P3) 58 (P10) 30 (P5) 18 (P25) 22 (<P3) 40 (<P3)
OFC (cm) 53.5 (P10) 44 (<P3) 54 (P50) 45.7 (<P3) 43 (<P3) 56 (P97)
Intellectual disability† ++ + ++ ++ ++ +++ 6/6
Hypotonia + + + ++ + + 6/6
Brain imaging − − A EV, CP A, EV A 4/6
High anterior hairline + + + + + + 6/6
Narrow palpebral fissures + + + − + + 5/6
Microcornea‡ − + − − + + 3/6
Flat malae + + + + + + 6/6
Broad nasal ridge and tip + + + + + + 6/6
Smooth philtrum/thin vermillion + + + + + + 6/6
Teeth WS, AE WS WS WS, AE WS, AE WS, AS 6/6
Large ears + + + + + + 6/6
Hearing loss§ + + + + + − 5/5
Scoliosis + ++ + − ++ + 5/6
Short fingers/toes + + + + + + 6/6
Palmar/plantar grooves, pillowing + + + + + + 6/6
Marked foetal finger/toe pads + + + + + + 6/6
Subcalcaneal fat pads + + + + + + 6/6
*Centiles between brackets.
†+IQ 50–60 ++IQ 35–50 +++IQ <35 (IQ data from publications,1–3 formal testing in patient 5, and estimated in patient 6).
‡Cornea diameter<10.0 mm.
§Hearing loss was evaluated by audiometry.
+, abnormality present; −, abnormality not present; A, central atrophy; AE, abnormal dental eruption; CP, choroid plexus papilloma; EV, enlarged ventricles; OFC, occipital frontal
circumference; WS, widely spaced; X, no data available.
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Triton X-100 and Roche complete protease inhibitor (buffer A);
insoluble material was removed by centrifugation. The complex
was bound to Flag resin (Sigma), washed three times with buffer
A, three times with buffer B (50 mM Tris/Cl pH 7.5, 300 mM
potassium acetate, 5% v/v glycerol) and three times with buffer
C (50 mM Tris/Cl pH 7.5, 50 mM potassium acetate, 5% v/v
glycerol, 0.5 mM tris (carboxyethyl) phosphine (TCEP)). The
complex was eluted from the resin by overnight cleavage at 4°C
with TEV protease in buffer C.
mRNA expression
We analysed TBL1XR1 mRNA expression in brain tissue (hypo-
thalamus; pituitary gland), in white and brown adipose tissue,
in muscle tissue and in liver tissue. In addition we analysed
TBL1XR1 RNA expression in lymphocytes of two patients (aged
13 and 20 years, respectively) and four controls (age between
25 and 30 years).
Tissues
Three hypothalami and pituitaries were obtained from the
Netherlands Brain Bank in accordance with permission for brain
autopsy and the use of human brain material and clinical infor-
mation for research purposes. Three unﬁxed, frozen (−80°C)
hypothalamus–pituitary specimens were used for mRNA expres-
sion. The paraventricular nucleus (PVN) region was cut in serial,
coronal 50 μm sections from unﬁxed frozen hypothalami on a
Figure 1 Face and extremity features
in individuals with Pierpont syndrome.
Note (A) the high forehead, narrow
palpebral ﬁssures, ﬂat malae, broad
nasal ridge and tip, thin upper
vermillion and large ears (upper row,
left to right: patients 1, 2 and 3; lower
row, left to right: patients 4, 5 and 6);
(B) marked grooves and pillowing of
hands and feet, and subcalcaneal fat
pads (upper row, left to right: patients
2, 4 and 6; lower row, left to right:
patients 2, 4 and 6).
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cryostat and the PVN area macroscopically dissected, collected,
and stored at −80°C until processing, as previously reported.10
RNA was extracted from the PVN and from homogenised pituit-
aries using TriReagent (Sigma) per manufacturer’s instructions,
followed by DNase treatment (Qiagen GmbH, Germany). cDNA
was synthesised with an Applied Biosystem Kit. White adipose
tissue cDNA was kindly provided by Drs M Serlie and M
Kilicarslan (Department of Endocrinology, AMC, Amsterdam)
and synthesised from RNA isolated from subcutaneous, perium-
bilical adipose tissue biopsies from healthy lean men under local
anaesthesia (approved by the Medical Ethics Committee of the
Academic Medical Centre in Amsterdam). Liver tissue cDNAwas
kindly provided by Drs M Serlie and P Gilijamse (Department of
Endocrinology, AMC, Amsterdam) and synthesised from RNA
isolated from liver tissue biopsies obtained during gastric bypass
surgery (approved by the Medical Ethics Committee of the
Academic Medical Centre in Amsterdam). RNA was isolated
using TRIzol reagent (Invitrogen, Breda, the Netherlands) fol-
lowed by the NucleoSpin RNA extraction kit (Machterey &
Nagel GmbH, Duren) and DNase treatment (Ambion, Carlsbad,
California, USA). cDNA was synthesised using Transcriptor First
Strand cDNA Synthesis Kit (Roche) according to the manufac-
turer’s instructions. Brown adipose tissue biopsies were taken
during thyroid surgery (approved by the Medical Ethics
Committee of the University Medical Centre Maastricht) and the
samples were kindly provided by Drs E Nascimento, E Broeders,
N Bouvy, P Schrauwen and W van Marken Lichtenbelt
(Maastricht University). RNA was isolated on the Magna Pure
(Roche Molecular Biochemicals, Mannheim, Germany) using the
Magna Pure LC mRNA tissue kit. The protocol and buffers
supplied with the corresponding kit were applied. cDNA synthe-
sis was performed using the Transcriptor cDNA Synthesis Kit for
RT-PCR with oligo d(T) primers (Roche Molecular Biochemicals,
Mannheim, Germany). Muscle cDNAwas commercially available
and obtained from Clontech, Takara (Mountain View, California,
USA). RNA from whole blood of four healthy controls and two
patients was isolated using the High Pure RNA Isolation Kit
(Roche Molecular Biochemicals, Mannheim, Germany) according
to the manufacturer’s protocol. cDNA synthesis was performed
using the Transcriptor cDNA Synthesis Kit for RT-PCR with
oligo d(T) primers (Roche Molecular Biochemicals, Mannheim,
Germany). From every sample a –RT reaction was performed in
order to check for genomic DNA contamination.
PCR
Primers were designed to amplify TBL1XR1 transcript
(NM_024665.4, F: 50-CCATGGCCAGTCCACTACAG-3, R:
50-TCCAGCACTTGGTGAACAGA-30), product size 126 bp, and
annealing temperature 65°C. Real-time PCR was performed
using the Lightcycler480 and Lightcycler480SybrGreen I Master
mix (Roche Molecular Biochemicals, Mannheim). Melting curve
analysis was performed and product size was determined by
DNA gel analysis. All samples contain mRNA as checked by
HPRT expression (hypoxanthine phosphoribosyl transferase, a
housekeeping gene).10 Expression levels in whole blood were
quantiﬁed using the LinReg software.11 The mean efﬁciency was
calculated for each assay and samples that had a deviation of
more than 5% were excluded. Calculated values were normalised
by HPRTexpression.
Figure 2 (A) Surface representation
of the transducin β-like 1 X-linked
receptor 1 (TBL1XR1) WD40 domain
(PDB ID 4LG9), the mutated residue
(Y446) is shown in cyan. (B)
Comparison of Y446 in human
TBL1XR1 (cyan) and f446 in yeast
(purple). (C) Representation of the
TBL1XR1/HDAC3/GPS2-SMRT chimaera
complex. (D) sodium dodecyl sulfate
polyacrylamide gel electrophoresis
(SDS–PAGE) of the puriﬁcation of the
wild-type and mutant TBL1XR1/
HDAC3/GPS2-SMRT chimaera complex.
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RESULTS
Study cohort
Patient 5 was the term, ﬁrst-born child of healthy, non-
consanguineous parents. She had intrauterine growth retard-
ation, was hypotonic at birth, and had bilateral hip dislocations.
She experienced feeding difﬁculties with gastrostomy placement
in infancy, and followed a markedly delayed motor and cogni-
tive development. She was able to walk with assistance, and had
no speech. Formal cognitive testing at age 7 years showed her
IQ to be 45. Hearing loss was detected in the ﬁrst year of life.
She gradually developed a progressive thoracolumbar scoliosis
requiring rod placement at age 10 years. Her postnatal growth
in height and of skull circumference was decreased. Onset of
menses was at the age of 11 years. Both her unusual face and
the abnormal creases of palms and soles were evident at birth.
She has always had mild fat pads anteromedial to both heels.
Patient 6 was the ﬁrst-born child of healthy, non-
consanguineous parents. She was remarkably hypotonic at birth.
At that time it was noticed that she had unusual facial morph-
ology, broad thumbs, deep pillowing of palms and soles, and
bilateral talipes. Her development was markedly delayed from
early on: she never developed any speech and had no sphincter
control. Formal cognitive testing was not possible, but her IQ
was estimated to be below 35 at age 18 years. She had increas-
ingly decreased growth in height, a relatively large head, low
body weight and little subcutaneous fat tissue. She gradually
developed pectus excavatum and thoracic scoliosis, but other-
wise had no signiﬁcant health problems.
Molecular analysis
Whole-exome sequencing yielded a single missense mutation
c.1337A>C in TBL1XR1 located at 3q26.32, resulting in the
amino acid substitution p.Tyr446Cys (Y446C) in all four
patients studied, but not in the parents of one of them (see
online supplementary table S1). No other potentially pathogenic
variant in the same gene was present in all four patients. Sanger
sequencing demonstrated the same mutation in the two other
patients. All other parents tested negative for the mutation using
Sanger sequencing, indicating de novo occurrence. The muta-
tion was at an evolutionary conserved position (ﬁgure 2A) and
absent in control populations (dbSNP, 1000 genomes, NHBLI,
ESP, GoNL).
Stability of mutated complexes
TBL1XR1 is a highly conserved protein found in all eukaryotes
(see online supplementary ﬁgure S1). It contains two structured
domains: an amino-terminal domain that mediates tetramerisa-
tion of the protein and a carboxy-terminal WD40 domain.
The TBL1XR1 tyrosine-to-cysteine mutation identiﬁed here is
located in the WD40 domain on one side of the inner surface of
the WD40 ring (ﬁgure 2A). Y446 is largely exposed to solvent,
and mutation to cysteine would not be expected to signiﬁcantly
perturb the structure of the domain. A tyrosine in this position is
found in nearly all TBL1XR1 proteins, although the equivalent
residue is a phenylalanine in the homologous Sif2 protein from
Saccharomyces cerevisiae. The structure of the WD40 domain
from Sif2 has also been reported.12 Despite relatively low
sequence identity between TBL1XR1 and Sif2, the structures of
their WD40 rings itself are similar. Furthermore, the yeast
residue equivalent to Y446, f446, adopts a very similar conform-
ation (ﬁgure 2B) suggesting a conserved function for this largely
non-polar amino acid. To conﬁrm that the Y446C mutation does
not grossly perturb the fold and behaviour of TBL1XR1 we
examined the ability of the TBL1XR1 to assemble correctly with
the GPS2:SMRT:HDAC3 complex. As predicted, the mutant
protein was readily expressed and puriﬁed and assembled cor-
rectly into the TBL1XR1:GPS2:SMRT:HDAC3 complex (ﬁgure
2C and D), suggesting that the molecular pathology of the
Y446C mutation is an impaired protein–protein interaction with
an as yet unidentiﬁed molecular partner rather than a failure to
fold correctly.
mRNA expression
TBL1XR1 mRNA expression was well visible in the pituitary
and the PVN area of the hypothalamus, as well as in liver and
muscle tissue and both white and brown adipose tissue, ﬁtting
the clinical symptomatology of Pierpont syndrome (ﬁgure 3A, B).
Figure 3 (A) Transducin β-like 1 X-linked receptor 1 (TBL1XR1) mRNA expression in human pituitary and hypothalamic PVN. (B) TBL1XR1 mRNA
expression in human white and brown adipose tissue, liver and muscle tissue. TBL1XR1 transcript PCR product on 2% agarose gel. The expected
product is 126 bp. BAT, brown adipose tissue; PIT, pituitary; PVN, paraventricular nucleus; WAT, white adipose tissue.
Figure 4 Relative expression of transducin β-like 1 X-linked receptor
1 (TBL1XR1) mRNA to hypoxanthine phosphoribosyl transferase (used
as reference gene) in leucocytes of patients (closed circles) and controls
(open circles). Individual values are depicted and mean values ±SD is
represented by a solid line.
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TBL1XR1 mRNA expression in whole blood was lower in
patients compared with controls (ﬁgure 4). The small number
of patients available for analysis precludes statistical analysis to
determine whether this difference is signiﬁcant.
DISCUSSION
In this study, we found a single TBL1XR1 missense mutation in
six patients with Pierpont syndrome that was absent in their
unaffected parents.
TBL1XR1, a member of the WD40 repeat-containing protein
family, is composed of 18 exons.13 The product of TBL1XR1,
TBL1XR1 (or TBLR1; 55 595 Da; 514 amino acids), contains a
carboxy-terminal WD40 domain containing eight WD40
repeats and an amino-terminal LisH domain that mediates tetra-
merisation of the protein and its interactions with NCoR/SMRT
and GPS2.13 14 TBL1XR1 is an essential component of the
NCoR/SMRT corepressor complex (ﬁgure 2C), which interacts
with nuclear hormone receptors, a family of ligand-dependent
transcription factors involved in regulation of gene transcription
(ﬁgure 5).15 When bound to unliganded nuclear hormone
receptors, corepressors mediate silencing of gene transcription
by recruiting chromatin-modifying enzymes. When a nuclear
hormone receptor is liganded, corepressors dissociate to relieve
repression of transcription. In negatively regulated target genes,
corepressors are essential for activation of transcription.16 The
WD40 repeats in TBL1XR1 are thought to be involved in the
interaction of the corepressor complex with histones stabilising
the association of the complex with the chromatin.13 17
TBL1XR1 also may play a regulatory role in the NF-κB
pathway and Wnt-mediated transcription. NF-kB transcription
requires IKKα to phosphorylate SMRT on chromatin, which
recruits TBL1XR1 to the gene promoter. During depletion of
TBL1XR1, NF-kB transcription and cell survival are compro-
mised.17 18 TBL1XR1 also recruits β-catenin to the Wnt target-
gene promoter. In the presence of TBL1XR1, β-catenin is able
to remove corepressors from the promoter of Wnt target genes
by competitive binding, thereby activating transcription.19
TBL1XR1 mutations have been implicated in several pheno-
types. Recurrent TBL1XR1 mutations have been described in
DNA of lymphatic malignancies, including primary central
nervous system lymphomas,20 21 acute lymphoblastic leukae-
mia22 and Sézary syndrome.23 The precise mechanisms by
which TBL1XR1 mutations contribute to tumourigenesis remain
unclear, but it has been hypothesised that loss of TBL1XR1
could compromise the ability of corepressor complexes to
inhibit receptor activity, leading to increased activation of recep-
tor target genes.22 In addition, it has been suggested that
TBL1XR1 might act as a tumour-suppressor gene in the lymph-
atic system,21 and upregulates VEGF-C inducing lymphangio-
genesis in oesophageal squamous cell carcinoma.24 Contrarily,
TBL1XR1 has been nominated as a novel breast cancer onco-
gene,25 indicating that any role of TBL1XR1 in tumourigenesis
is tissue-speciﬁc.
Whole-exome sequencing of 209 children with autism spec-
trum disorder (ASD) and their parents showed a de novo
p.Leu282Pro mutation in TBL1XR1 in one child, who also had
intellectual disability.26 Subsequently, evaluation of 44 candidate
genes in 2494 ASD cases identiﬁed two de novo TBL1XR1
mutations (p.Leu282Pro, p.Ile397SerfsX19).27 Apart from intel-
lectual disability, however, these patients had no features in
common with Pierpont syndrome (B O’Roak and E Eichler, per-
sonal communication 2013). Similarly, a non-dysmorphic
patient with intellectual disability, autism and West syndrome
was found to have a de novo p.Gly70Asp mutation in
TBL1XR1.28 Three patients, including a mother and child, have
been described with a deletion involving only TBL1XR1 in
patients who had mild to moderate intellectual disability
without autistic behaviour or manifestations of Pierpont syn-
drome.29 30 In addition, three cases with small deletions involv-
ing TBL1XR1 and other genes are included in the Decipher
database (http://decipher.sanger.ac.uk/). All had intellectual dis-
ability, ASD or ASD-like behaviour but lacked physical signs of
Figure 5 Schematic model of transcriptional regulation by the SMRT/
nuclear receptor corepressor (NCoR) complex.
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Pierpont syndrome (Z Stark, M Decamp, B Dallapiccola, per-
sonal communications, 2014). In one additional published
patient the phenotype was attributed to a 2.2 Mb deletion at
3q26.3 involving TBL1XR1, but an updated annotation showed
that the deletion did not encompass TBL1XR1.31 This suggests
that the phenotype of individuals with a microdeletion 3q26.3
is caused by a loss of function of TBL1XR1, and consists of
intellectual disability and frequently ASD, and a phenotype that
shows no resemblance to Pierpont syndrome. It remains at
present uncertain whether the abundant hypothalamic and pitu-
itary mRNA expression of wild-type TBL1XR1 reported here is
related to the intellectual disability in individuals with deletions.
The differences in phenotype in subjects with the Y446C
mutation compared with subjects with whole-gene deletions or
other TBL1XR1 mutations suggest different pathogenic mechan-
isms. The Y446C mutation could act in a dominant negative
way, in agreement with our ﬁnding that the mutant TBL1XR1
Y446C protein is able to assemble into the HDAC3 corepressor
complex. Since TBL1XR1 Y446C can form hetero-tetramers
with wild-type TBL1XR1, TBL1XR1 Y446C will likely be
present in most HDAC3 corepressor complexes, and the
impaired or inappropriate protein–protein interactions with an
as yet unidentiﬁed molecular partner will likely be present
ubiquitously.
In conclusion, one speciﬁc TBL1XR1 missense mutation is
responsible for the phenotype in individuals with Pierpont syn-
drome. The difference in phenotype between non-ASD Pierpont
patients with the Y446C mutation in TBL1XR1 and individuals
with a complete deletion or other mutation of TBL1XR1 sug-
gests mutation-speciﬁc mechanisms of pathogenesis for ASD.
Further studies of the pathogenesis in individuals with deletions
and various mutations in TBL1XR1 could yield useful insights
into the pathogenesis of ASD.
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